Industry Newscircular rnacar tlillylipid nanoparticles
Lilly Acquires Orna Therapeutics For $2.4 Billion
|
5.6
On February 9, Eli Lilly announced an agreement to acquire Orna Therapeutics in a deal valued at up to $2.4 billion in cash, and its shares rose more than 3% in morning trading. Orna’s circular-RNA platform aims to enable patients’ cells to generate therapies in vivo; its lead candidate ORN-252 is an early-stage CAR-T targeting CD19 delivered via novel lipid nanoparticles.
Scoring Rationale
Notable strategic acquisition with credible company announcement, but limited AI/ML relevance reduces broader industry significance.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
